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1643Prognostic Value of Fractional Flow Reserve
Linking Physiologic Severity to Clinical OutcomesABSTRACTBACKGROUND Fractional ﬂow reserve (FFR) has become an established tool for guiding treatment, but its graded
relationship to clinical outcomes as modulated by medical therapy versus revascularization remains unclear.
OBJECTIVES The study hypothesized that FFR displays a continuous relationship between its numeric value and
prognosis, such that lower FFR values confer a higher risk and therefore receive larger absolute beneﬁts from
revascularization.
METHODS Meta-analysis of study- and patient-level data investigated prognosis after FFR measurement. An interaction
term between FFR and revascularization status allowed for an outcomes-based threshold.
RESULTS A total of 9,173 (study-level) and 6,961 (patient-level) lesions were included with a median follow-up of 16
and 14 months, respectively. Clinical events increased as FFR decreased, and revascularization showed larger net beneﬁt
for lower baseline FFR values. Outcomes-derived FFR thresholds generally occurred around the range 0.75 to 0.80,
although limited due to confounding by indication. FFR measured immediately after stenting also showed an inverse
relationship with prognosis (hazard ratio: 0.86, 95% conﬁdence interval: 0.80 to 0.93; p < 0.001). An FFR-assisted
strategy led to revascularization roughly half as often as an anatomy-based strategy, but with 20% fewer adverse events
and 10% better angina relief.
CONCLUSIONS FFR demonstrates a continuous and independent relationship with subsequent outcomes, modulated
by medical therapy versus revascularization. Lesions with lower FFR values receive larger absolute beneﬁts from
revascularization. Measurement of FFR immediately after stenting also shows an inverse gradient of risk, likely from
residual diffuse disease. An FFR-guided revascularization strategy signiﬁcantly reduces events and increases freedom
from angina with fewer procedures than an anatomy-based strategy. (J Am Coll Cardiol 2014;64:1641–54) © 2014 by the
American College of Cardiology Foundation.
 
Open access under CC BY-NC-ND license.M ost medical conditions form a continuumfrom nearly normal to extremely patho-logic, for example hypertension or hyper-
cholesterolemia. Often treatment of such graded
diseases offers only a dichotomous choice, like revas-
cularization in atherosclerotic coronary disease. The
spectrum of coronary artery disease (CAD) requires
a threshold of severity for making a binary decision
for 1 therapy (optimal medical therapy alone) or
another (addition of percutaneous coronary interven-
tion [PCI] or coronary artery bypass grafting [CABG]).SEE PAGE 1655Since its introduction more than 20 years ago (1),
fractional ﬂow reserve (FFR) has become an impor-
tant tool for selecting revascularization or medical
treatment alone for a coronary stenosis. On the basis
of comparisons to noninvasive stress tests, most le-
sions display some features of “ischemia” when the
FFR falls below 0.75 to 0.80 (2). Consequently,randomized outcomes trials of FFR utilized ﬁxed
cutoff values in this range (3–5). However, an
independent technique instead uses clinical out-
comes to deﬁne a threshold. Accordingly, an analysis
of prognosis with and without revascularization,
along the spectrum of FFR values, offers an appro-
priate and complementary alternative to the nonin-
vasive tests originally examined at the clinical
introduction of FFR.
The Central Illustration displays the conceptual
hypothesis for the current study. At near normal
(high) FFR values, event rates should be lowest and
the risk of PCI or CABG offers no or even negative net
beneﬁt (3,4). At lower FFR values tracking with
reduced ﬂow capacity, event rates should increase,
and revascularization provides growing beneﬁt
(5). Between the extremes of FFR, the 2 survival
curves cross, thereby deﬁning an outcomes-based
FFR threshold for treatment decisions without refer-
ence to noninvasive tests or other surrogate criteria.
CENTRAL ILLUSTRATION C
Similar to many continuous “bi
ﬂow reserve (FFR) potentially
Near normal (high) FFR values
revascularization procedures eq
(low) FFR values increase the r
percutaneous coronary interven
accrues in parallel. In between
outcomes-based FFR optimal t
ABBR EV I A T I ON S
AND ACRONYMS
CABG = coronary artery
bypass grafting
CAD = coronary artery disease
CI = conﬁdence interval
FFR = fractional ﬂow reserve
MACE = major adverse
cardiac event(s)
MI = myocardial infarction
PCI = percutaneous
coronary intervention
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ture, we sought to answer 3 questions linking
physiologic severity to prognosis. First, does
FFR provide a continuous and independent
marker for clinical outcomes? Second, can
FFR risk stratify prognosis for a coronary
stenosis as modulated by revascularization?
And, third, will the FFR value measured
immediately after PCI predict subsequent
events?
METHODSWe used 2 parallel and complementary types of
analysis. For the study-level meta-regression, each
published manuscript provided single data points of
summary values for the group mean FFR and subse-
quent major adverse cardiac event (MACE) rates. For
the patient-level meta-analysis on the basis of publi-
cations whose authors agreed to participate in this
collaborative project, raw data for every patientonceptual Relationship Between FFR and Outcomes
omarkers” such as blood pressure and lipids, fractional
relates to subsequent outcomes in a graded fashion.
indicate a favorable prognosis, where the risk from
uals or even exceeds any potential beneﬁt. Worse
isk of events such that the absolute beneﬁt from
tion (PCI) or coronary artery bypass grafting (CABG)
these extremes the curves cross, providing an
hreshold.served as single data points using lesion FFR value(s),
clinical characteristics, and subsequent events.
Comparing study- and patient-level analyses allows
for a more complete sampling of the published data
and identiﬁcation of common results.
PUBLISHED DATA SEARCH AND DATA COLLECTION.
The existing FFR literature was searched to identify
manuscripts with suitable outcomes data. The ﬁrst
author manually reviewed all PubMed abstracts
through February 12, 2014, which contained the terms
fractional ﬂow reserve or FFR, as well as all related
manuscripts and citations without abstracts. Any
match that studied humans and mentioned clinical
outcomes was ﬂagged for detailed review of the
whole manuscript. For multiple publications result-
ing from a common set of patients (e.g., serial follow-
up during a randomized trial), the most complete
manuscript with the longest length of follow-up was
selected.
For the study-level analysis, each manuscript was
examined for inclusion on the basis of the following
criteria: follow-up duration of at least 180 days to
ensure meaningful clinical observation, mean or
median FFR value provided for a homogeneous
treatment group (initial medical therapy versus re-
vascularization, but not mixed), and exclusion of
nonatherosclerotic disease (e.g., transplant vascul-
opathy or myocardial bridging) or culprit lesions in
acute myocardial infarction (MI). Papers that con-
tained 1 or more applicable cohorts (e.g., a study may
report a subset treated with medical therapy and
another subset treated by PCI) had typical de-
mographics, clinical history, lesion characteristics,
treatment modality, and clinical outcomes abstracted
for each group from the full manuscript. No ethics
board review was sought for the study-level analysis,
as it involved only aggregation of previously pub-
lished data.
For the collaborative patient-level analysis, we
attempted to contact the corresponding authors for
all FFR outcome manuscripts identiﬁed during the
literature search. Interested authors supplied dei-
dentiﬁed patient-level data in a standardized tem-
plate as allowed by the variables collected for each
study. No further ethics board review was sought for
the patient-level analysis because each included
study had already obtained it for the primary publi-
cation and the provided data contained no conﬁden-
tial identiﬁers.
Multiple lesions were allowed per patient, but only
1 lesion per major epicardial distribution (left anterior
descending coronary artery, left circumﬂex coronary
artery, or right coronary artery) plus any graft con-
duits. Included patients had to meet the following
37 studies included
6,061 total patients
6,961 total lesions
Attempted to
contact all
corresponding
authors
22 studies overlap
3,358 subjects overlap
3,426 lesions overlap
Full-text articles assessed
for eligibility
(n = 120)
PubMed search through February 12, 2014
for “fractional flow reserve” or “FFR”
(n = 925)
Patient-level analysis
51 studies included
90 distinct cohorts
8,418 total patients
9,173 total lesions
Study-level analysis
805 records excluded
374 lack outcome data
141 review articles
86 editorials
68 case reports
61 non-human studies
64 letters to the editor
11 non-cardiac







68 articles excluded
14 could not be retrieved
12 mixed medical and PCI/CABG
15 lacked mean FFR values
11 overlapped with prior work
7 contained only post-FFR
10 other reasons*






FIGURE 1 Details of PubMed Search
Details of PubMed search that led to study-level and patient-level data. *Other reasons for
exclusion were no (2 articles) or too short (1) follow-up, unclear or mixture of treatment
methods when describing outcomes (3), myocardial bridging (1), simulation-derived
fractional ﬂow reserve (FFR) (1), trial design (1), and meta-analysis (1). CABG ¼ coronary
artery bypass grafting; PCI ¼ percutaneous coronary intervention.
J A C C V O L . 6 4 , N O . 1 6 , 2 0 1 4 Johnson et al.
O C T O B E R 2 1 , 2 0 1 4 : 1 6 4 1 – 5 4 FFR and Outcomes
1645criteria: either a clinical event of known date or a
minimum of 180 days of MACE-free follow-up after
FFR measurement to ensure meaningful clinical ob-
servation; pre-treatment FFR value; recorded treat-
ment decision (medical or revascularization); and
exclusion of nonatherosclerotic disease or culprit le-
sions in acute MI. To explore the prognostic value
of post-revascularization FFR measurements, a small,
additional group of patients was included that had
only post-treatment FFR results. As variably collected
by each study, patient demographics, clinical history,
lesion characteristics, treatmentmodality, and clinical
outcomes were recorded.
Clinical events of interest to study- and patient-
level analyses were death, MI, and target lesion or
vessel revascularization. Clearly documented re-
vascularizations in off-target vessels were excluded as
being unrelated to the initial lesion studied by
FFR. Too few studies and patient-level data speciﬁed
cardiac versus noncardiac death to enable its separa-
tion. Similarly, myocardial infarction was inconsis-
tently noted if due to target vessel or elsewhere and
therefore could not be meaningfully distinguished.
Two composite MACE rates were studied: ﬁrst, the
triad of death, MI, and target lesion or vessel revas-
cularization; second, only death and MI. In the
patient-level meta-analysis, only the ﬁrst event was
included if several occurred.
GENERAL STATISTICAL METHODS. Statistical ana-
lyses were performed in R version 3.0.2 (R Founda-
tion for Statistical Computing, Vienna, Austria), using
the metafor package (version 1.9-2) for meta-analysis.
We used standard summary statistical tests. Quantile-
quantile plots identiﬁed the following continuous
variables as signiﬁcantly non-normal: FFR, weight,
body mass index, minimal lumen diameter, and
reference vessel diameter. Applicable tests were 2-
tailed, and p < 0.05 was considered statistically sig-
niﬁcant. Further statistical methods can be found in
the Online Appendix.
STUDY-LEVEL META-REGRESSION. For the study-
level meta-regression, length of follow-up was het-
erogeneous. To adjust for the differences, 2 methods
were compared. The simple method normalized each
MACE rate to 12 months. For example, 10 events in
100 subjects over 8 months would yield a normalized
MACE rate of [(10/100)/8]$12 ¼ 15% at 1 year. The
more complex method adjusted the normalized
event rates on the basis of a Poisson regression pre-
dicting MACE as a continuous function of length of
follow-up. Fixed and random (DerSimonian and
Laird) effects meta-regressions of the incidence rate
included the mean FFR value, revascularization as a
binary variable, and an interaction term. The optimaloutcomes-based threshold occurred at the intersec-
tion of the unrevascularized and revascularized ﬁtted
curves. Note that some intersections did not occur
within the plausible FFR range from 0 to 1, particu-
larly with small or parallel event rates between
treatment groups.
PATIENT-LEVEL META-ANALYSIS. To explore the
hypothesis that FFR might simply reﬂect de-
mographic characteristics, classic cardiovascular risk
factors, or basic angiographic features, we studied the
capability of other variables to predict the measured
FFR value in the patient-level data. Each variable
was studied in isolation using logistic regression
(quasibinomial link function in a generalized linear
model). Continuous predictors also were examined
using correlation methods, whereas binary predictors
summarized by median and interquartile range were
compared using the Mann-Whitney U test. Because
only quantitative percent diameter stenosis showed a
TABLE 1 Baseline Characteristics
Study-Level Analysis
p Value
Patient-Level Analysis
p ValueAll Cohorts Unrevascularized Revascularized All Patients Unrevascularized Revascularized
n (subjects) 8,418 (100) 5,041 (60) 3,377 (40) N/A 6,061 (100) 3,102 (51) 2,959 (49) N/A
n (lesions) 9,173 (100) 5,518 (60) 3,655 (40) N/A 6,961 (100) 3,729 (54) 3,232 (46) N/A
Follow-up, months 16 (12–30) 16 (12–30) 17 (10–30) 0.32 14 (12–32) 17 (12–38) 12 (7–27) <0.001
Demographics (per subject)
Age, yrs 63  11 63  11 63  10 0.28 64  11 65  11 63  11 <0.001
Male 71 68 75 <0.001 73 70 77 <0.001
Height, cm 169  9 167  10 171  9 <0.001
Weight, kg 77 (67–88) 75 (65–85) 79 (69–90) <0.001
Body mass index, kg/m2 28.1 (25.0–31.0) 28.4 (25.1–31.5) 27.8 (24.9–30.5) 0.001 26.4 (24.1–29.4) 26.0 (23.9–29.4) 26.8 (24.3–29.4) 0.012
Country (over 19 total) <0.001 <0.001
Belgium 10 13 7 23 28 19
Canada 5 6 3 6 8 4
China 1 <1 2 1 <1 2
Denmark 2 <1 5
France 4 5 4 17 20 15
Germany 2 2 2 5 2 8
Greece 1 1 <1 1 1 <1
Israel 2 2 2
Italy 2 2 2
Japan 4 3 4 5 3 8
Korea 9 11 6 6 6 5
the Netherlands 2 2 3 11 9 13
Poland <1 <1 <1
Portugal 3 5 <1 <1 <1 <1
Spain 6 8 2 8 10 5
Sweden <1 <1 1
Turkey 2 4 <1 4 8 1
United Kingdom 1 <1 2 2 <1 3
United States 17 18 14 6 3 10
Multicountry study 31 18 47
Risk factors
Diabetes 28 30 26 0.001 26 26 27 0.28
Hypertension 60 59 60 0.62 58 59 56 0.038
Tobacco 34 32 35 0.006 42 43 42 0.57
Dyslipidemia 61 60 64 <0.001 61 60 62 0.15
Family CAD 33 28 38 <0.001 27 23 31 <0.001
History
Multivessel CAD 38 36 41 0.001 59 51 68 <0.001
Prior MI 27 26 30 0.003 33 30 37 <0.001
Prior PCI 30 30 32 0.24 31 28 35 <0.001
Prior CABG 3 3 4 0.26 5 6 4 0.038
Medications
Antiplatelet 87 85 89 <0.001 89 89 90 0.38
Beta blocker 65 64 67 0.20 66 64 69 0.005
Calcium blocker 32 33 31 0.64 25 26 24 0.46
Nitrates 51 50 51 0.83 27 25 30 0.014
ACE inhibitor 55 52 59 0.001 54 57 51 0.001
Statin 67 67 67 1.00 72 73 71 0.38
Continued on the next page
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1646clinically relevant association with FFR, the adjusted
model added this single variable. Additional adjust-
ment for the type of revascularization (e.g., bare-
metal stent, drug-eluting stent, unspeciﬁed PCI, or
CABG) produced similar FFR thresholds. In the subsetwith post-PCI measurements, we found no signiﬁcant
interaction between FFR and the revascularization
technique. Additional adjustment for the type of
revascularization did not signiﬁcantly alter the prog-
nostic value of FFR in this subset. Multiple
TABLE 1 Continued
Study-Level Analysis
p Value
Patient-Level Analysis
p ValueAll Cohorts Unrevascularized Revascularized All Patients Unrevascularized Revascularized
Presentation characteristics
Ejection fraction, % 60  12 60  11 60  13 0.08 61  13 62  13 61  13 0.07
Presentation <0.001 <0.001
Stable 71 64 89 68 64 74
Unstable angina 15 18 8 20 23 16
NSTEMI 13 16 3 9 9 9
STEMI 1 2 <1 3 4 1
CCS angina 2.4  1.1 2.1  1.0 2.6  1.1 <0.001 <0.001
No angina 9 18 3
Class I 16 15 16
Class II 45 45 45
Class III 23 16 28
Class IV 7 5 8
NYHA heart failure <0.001
No heart failure 29 30 29
Functional class I 42 55 29
Functional class II 23 13 33
Functional class III 6 2 9
Functional class IV <1 <1 <1
Procedure characteristics (per lesion)
Vessel <0.001 <0.001
LMCA 10 10 9 7 8 7
LAD 57 59 54 57 58 55
LCx 14 14 15 15 16 15
RCA 18 16 22 19 17 22
Graft (IMA, SVG, radial) <1 <1 <1 1 1 1
In-stent restenosis 20 22 18 0.17 4 3 5 0.008
%DS by QCA 51  15 46  12 56  16 <0.001 52  18 44  13 63  19 <0.001
MLD, mm 1.44 (1.03–1.91) 1.66 (1.28–2.07) 1.19 (0.85–1.69) <0.001 1.35 (1.00–1.70) 1.50 (1.26–1.81) 1.06 (0.75–1.44) <0.001
RVD, mm 3.00 (2.51–3.54) 3.06 (2.55–3.65) 2.94 (2.49–3.42) <0.001 2.90 (2.49–3.31) 2.85 (2.45–3.30) 2.99 (2.50–3.40) 0.014
Pd, mm Hg 71  17 83  14 63  15 <0.001 77  17 82  16 67  15 <0.001
Pa, mm Hg 94  16 94  15 94  17 0.77 94  17 94  17 93  17 0.28
FFR 0.80 (0.69–0.88) 0.87 (0.82–0.91) 0.69 (0.61–0.77) <0.001 0.81 (0.71–0.88) 0.87 (0.83–0.92) 0.70 (0.59–0.76) <0.001
FFR post-PCI 0.92 (0.87–0.96) N/A 0.92 (0.86–0.96) N/A
Hyperemia <0.001 <0.001
IC adenosine 42 51 28 59 71 48
IV adenosine 14 10 20 38 27 47
IC or IV adenosine 41 35 49
ATP or papaverine 4 4 3 3 1 5
Revascularization method N/A N/A
BMS 21 30
CABG 4 11
DES 9 27
PCI 44 30
CABG or PCI 14
Other (POBA, DEB) 9 2
Values are n (%), median (interquartile range), mean  SD, %.
ACE ¼ angiotensin-converting enzyme; ATP ¼ adenosine triphosphate; BMS ¼ bare-metal stent(s); CABG ¼ coronary artery bypass grafting; CAD ¼ coronary artery disease; CCS ¼ Canadian
Cardiovascular Society; DEB ¼ drug-eluting balloon; DES ¼ drug-eluting stent(s); %DS ¼ percent diameter stenosis; FFR ¼ fractional ﬂow reserve; IC ¼ intracoronary; IMA ¼ internal mammary
artery; IV ¼ intravenous; LAD ¼ left anterior descending coronary artery; LCx ¼ left circumﬂex coronary artery; LMCA ¼ left main coronary artery; MLD ¼ minimal lumen diameter; N/A ¼ not
applicable; NSTEMI ¼ non-ST-segment elevation myocardial infarction; NYHA ¼ New York Heart Association; Pa ¼ aortic pressure; Pd ¼ distal coronary pressure; PCI ¼ percutaneous coronary
intervention; POBA ¼ plain old balloon angioplasty; QCA ¼ quantitative coronary angiography; RCA ¼ right coronary artery; RVD ¼ reference vessel diameter; STEMI ¼ ST-segment elevation
myocardial infarction; SVG ¼ saphenous vein graft.
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FIGURE 2 FFR Distributions
(A) Study-level analysis. Each point details the mean (squares) and SD (horizontal lines) for fractional ﬂow reserve (FFR) in a published cohort
treated with either revascularization (red) or medical therapy (slate). Note that sample sizes varied markedly among cohorts (over 100-fold),
and Online Table 1 provides further details. The shaded region denotes FFR 0.75 to 0.80. (B) Patient-level analysis. Lesion-level histogram of
FFR values from the patient-level analysis treated with either revascularization (red) or medical therapy (slate). Note that some patients
contributed more than 1 lesion and some total occlusions were assigned a value of 0.50. The shaded region denotes FFR of 0.75 to 0.80.
Abbreviations as in Figure 1.
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1648imputation was not used due to the sizable number of
missing ﬁelds for covariates with a statistically or
clinically insigniﬁcant association with FFR.
For the patient-level meta-analysis, length of
follow-up was also heterogeneous. Therefore, we
primarily performed a time-to-event analysis using
a Cox proportional hazards model. However, to
examine the dependence of our ﬁndings on the spe-
ciﬁc model, we also entered binary events within
12 months into a logistic regression model. For both
Cox and logistic models, the optimal outcomes-based
threshold was determined from the coefﬁcients as
the intersection of the unrevascularized and revascu-
larized ﬁtted curves. Initially, themodel only included
the lesion-speciﬁc FFR value, revascularization as a
binary variable, and an interaction term. Next, the
model was expanded to adjust for percent diameter
stenosis in the subset of lesions with that information.
The size of the patient-level data allowed for
exploration of several important subsets. We re-
peated the previous analysis for the following sub-
groups: left main lesions, acute coronary syndromes
(unstable angina and acute MI), known diabetes
mellitus, graft conduits (internal mammary arteries,
free radial vessels, and saphenous veins), and in-
stent restenosis.PROGNOSTIC VALUE OF FFR MEASURED IMMEDIATELY
AFTER PCI. A subset of patient-level data provided
immediate post-PCI measurements of FFR, either in
conjunction with pre-PCI measurements (the vast
majority) or by themselves (a small minority). Due to
variable length of follow-up, we primarily performed
a time-to-event analysis using a Cox proportional
hazards model. Hazard ratios are expressed per 0.05
change of FFR, which equals half the interquartile
range. The basic model included only the post-PCI
measurement of FFR, whereas the adjusted model
added the pre-PCI measurement of FFR. For visual
presentation, we additionally divided the subset into
tertiles and compared Kaplan-Meier survival curves
using the log-rank test.
META-ANALYSIS OF STRATEGY-BASED STUDIES.
During the comprehensive literature review, manu-
scripts were identiﬁed that compared clinical out-
comes after a strategy-based approach between
FFR-assisted and anatomy-guided revascularization.
Event counts and angina status for each strategy were
extracted from the manuscript and used to summa-
rize the relative risk using ﬁxed and random effects
meta-analysis. The proportion of lesions treated
with revascularization was summarized for each
strategy.
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FIGURE 3 Outcomes as a Function of FFR Value
(A) Normalized 1-year major adverse cardiac event (MACE) rate for study-level analysis. Meta-regression for the study-level data ﬁts the normalized 1-year
MACE rate (circles whose size reﬂects the number of patients) for cohorts treated with either revascularization (red) or medical therapy (slate) as a function
of mean lesion FFR. Colored lines depict the meta-regression ﬁt. These curves cross at the optimal FFR threshold, shown here for a univariate model with
random effects. See Table 2 for results from other models. (B) Cox model 1-year MACE rate for patient-level analysis. Patient-level analysis ﬁts the
outcomes data to a Cox proportional hazards model of survival, shown here with the best-ﬁt 1-year MACE rate as a function of individual lesion FFR. Colored
lines depict the model ﬁt for revascularization (red) or medical therapy (slate) treatment. These curves cross at the optimal FFR threshold, here shown for
the unadjusted model. See Table 2 for results from other models. FFR ¼ fractional ﬂow reserve; MI ¼ myocardial infarction.
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PUBLISHED DATA SEARCH AND BASELINE CHAR-
ACTERISTICS. Figure 1 summarizes the published
data search and study inclusion leading to a total of
9,173 (study-level) and 6,961 (patient-level) lesions.
Table 1 summarizes demographics, clinical details,
lesion characteristics, and treatment methods for
study- and patient-level data. Online Table 1 details
which manuscripts were included for the study-level
analysis, and Online Table 2 details those papers for
which patient-level data were provided as part of the
collaborative analysis. Not all studies collected or
provided information for every parameter. Although
the vast majority of 6,061 subjects only had a single
lesion examined by FFR, in 589 subjects (10%), 2
lesions underwent FFR, and in 151 subjects (2%), 3 or
more lesions underwent FFR.
FFR DISTRIBUTION. Figure 2A depicts the mean and
spread of FFR values for each cohort in the study-
level meta-regression, ordered ﬁrst by received
treatment (medical versus revascularization) and
second by mean lesion severity. Figure 2B shows the
lesion-level histogram from the patient-level
data. Very few lesions with FFR <0.75 received
medical treatment, comprising only 67 of the 3,729patient-level lesions (2%). Conversely, a small mi-
nority of lesions with FFR >0.80 were treated with
revascularization, making up 309 of the 3,150 lesions
(10%). A transition in treatment patterns occurred in
the FFR 0.75 to 0.80 range, containing 1,062 of the
6,879 lesions (15%).
PREDICTION OF FFR. As detailed in Online Table 3,
several variables were associated with FFR values in
the patient-level data. However, most of the statis-
tically signiﬁcant associations were either negligible,
with correlation coefﬁcients of #0.10 (implying that
the parameter explains at most 0.12 or 1% of the
group variation in FFR), or clinically insigniﬁcant,
with FFR differences #0.04 between groups (equal
to the 95% limits of agreement for repeated FFR
measurements of the same lesion made minutes
apart) (6). Only 2 variables showed both statistically
and clinically signiﬁcant associations with FFR:
quantitative percent diameter stenosis (Pearson cor-
relation coefﬁcient –0.56; p < 0.001) and minimal
lumen diameter (Pearson correlation coefﬁcient
0.49; p < 0.001). Given the highly collinear nature of
these 2 variables, only the stronger percent diameter
stenosis was used for an adjusted model. Its coefﬁ-
cient of determination equals 0.562 or 31%, implying
that less than one-third of the population variation
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FIGURE 4 FFR Measurements Made Immediately After PCI
(A) Histogram. Lesion-level histogram of post–PCI FFR values from the
(B) Survival curves. Kaplan-Meier event curves for tertiles of post-PCI F
and tertile-based log-rank tests demonstrated a signiﬁcant (p < 0.001)
events. Abbreviations as in Figures 1 and 2.
TABLE 2 FFR Thresholds on The Basis of Outcomes Using Various Models
Model
FFR Threshold
(Composite MACE)
FFR Threshold
(Death, MI Only)
Study Level Meta-Regression
Fixed effects (n ¼ 8,418 patients), unadjusted N/A* N/A
Adjusted 0.90 0.90
Random effects, unadjusted 0.75† 0.75
Adjusted 0.90 0.90
Patient Level Meta-Analysis
Cox model (n ¼ 5,979 total patients), unadjusted 0.67‡ N/A
Adjusted 0.76 0.49
Logistic model, unadjusted 0.62 N/A
Adjusted 0.75 N/A
Logistic model with random effects, unadjusted 0.69 N/A
Adjusted 0.72 N/A
Important Subgroups of Patient-Level Meta-Analysis (Cox Model)
Left main s2tenosis (n ¼ 511 patients), unadjusted 0.86 0.83
Adjusted 0.84 0.82
Acute coronary syndrome (n ¼ 1,196 patients), unadjusted 0.81 N/A
Adjusted 0.83 0.75
Diabetes mellitus (n ¼ 1,511 patients), unadjusted 0.79 N/A
Adjusted 0.77 0.50
Graft conduits (n ¼ 92 patients), unadjusted 0.87 0.94
Adjusted N/A N/A
In-stent restenosis (n ¼ 120 patients), unadjusted 0.88 0.48
Adjusted 0.77 0.63
*N/A indicates that model did not converge to a threshold value within the fractional ﬂow reserve (FFR) range
from 0 to 1. †Figure 3A depicts raw data and ﬁt leading to this threshold. ‡Figure 3B depicts best ﬁt leading to
this threshold.
MACE ¼ major adverse cardiac event(s); MI ¼ myocardial infarction.
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severity.
CLINICAL OUTCOMES. Figure 3A shows the normal-
ized 1-year MACE rate from the study-level
meta-regression. The optimal FFR threshold for a
composite of death, MI, and revascularization
occurred at 0.75, rising to 0.90 after Poisson adjust-
ment for variable length of follow-up, suggesting a
sensitivity to how events are temporally distributed
after the procedure. Figure 3B depicts the 1-year
MACE rate on the basis of the unadjusted Cox
regression from the patient-level meta-analysis. The
optimal FFR threshold for a composite of death, MI,
and revascularization occurred at 0.67, rising to 0.76
after adjustment for percent diameter stenosis, likely
due to its signiﬁcant correlation with FFR as detailed
previously.
Table 2 summarizes the results from study- and
patient-level analyses focusing on different end-
points (composite MACE versus only death and MI
alone), speciﬁc subgroups (e.g., left main or acute
coronary syndrome), covariate adjustment (unad-
justed vs. adjusted for percent diameter stenosis),
and statistical model (Cox proportional hazards vs.
logistic regression). Further results can be found in
the Online Appendix for more complex approaches
such as constrained regression and random effects
within subjects (to account for multiple coronary
lesions belonging to the same patient).Time Since PCI (Years)
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966 patients with
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, inverse relationship between post-PCI FFR and subsequent clinical
TABLE 3 Summary of Published Data Comparing FFR-Guided or FFR-Assisted Strategy to an Anatomy-Based Strategy
First Author
(Study) (Ref. #)
Number of Patients Relative Outcome*
Frequency of
PCI or CABG
FFR Anatomy Composite MACE† Freedom From Angina‡ FFR Anatomy
Randomized Trials Comparing FFR to Angiography
Pijls (DEFER) (3) 91 90 0.69 (95% CI: 0.43–1.11) 1.15 (95% CI: 0.91–1.46) 0% 100%
Pijls (FAME) (14) 509 496 0.80 (95% CI: 0.62–1.02) 1.05 (95% CI: 0.98–1.13) 58% 92%
Observational Studies Comparing FFR to Angiography
Wongpraparut et al. (15) 57 80 0.37 (95% CI: 0.15–0.93) NR 41% 100%
Puymirat et al. (16) 222 495 0.46 (95% CI: 0.31–0.68) NR 35% 100%
Li et al. (17) 1,090 6,268 0.85 (95% CI: 0.71–1.01)§ NR 34% 100%
Di Seraﬁno et al. (18) 65 158 0.47 (95% CI: 0.30–0.75) 1.31 (95% CI: 1.01–1.71) 35% 57%
Toth et al. (19) 198 429 0.97 (95% CI: 0.59–1.59) 1.95 (95% CI: 1.36–2.79) 518 vs. 1373
graft conduits
Park et al. (20) 2,178 2,178 0.55 (95% CI: 0.43–0.70) NR 30 vs. 46 mm
total stent length
Observational Studies Comparing FFR to IVUS
Nam et al. (21) 83 94 1.13 (95% CI: 0.23–5.46) NR 34% 91%
de la Torre Hernandez et al. (22) 400 400 1.06 (95% CI: 0.56–1.98) NR 28% 49%
Meta-Analysis of Studies in this Table Comparing FFR to Anatomy
All 10 studies listed (ﬁxed effects) 4,893 10,688 0.83 (95% CI: 0.78–0.87) 1.10 (95% CI: 1.03–1.17) 42% 95%
(Random effects) 0.71 (95% CI: 0.59–0.86) 1.22 (95% CI: 1.02–1.45)
*Risk, hazard, or odds ratio depending on publication; however, meta-analysis used published data to compute and summarize relative risk for all studies (see statistical
methods section for details). †All rows represent composite major adverse cardiac events (MACE) (death, myocardial infarction [MI], revascularization) except where noted;
values <1 favor fractional ﬂow reserve (FFR) (lower rate of MACE), while values >1 favor anatomy. ‡Values >1 favor FFR (superior freedom from angina), while values <1 favor
anatomy. §Endpoint of death plus MI only (no revascularization).
CI ¼ conﬁdence interval; IVUS ¼ intravascular ultrasound; NR ¼ not reported; other abbreviations as in Table 1.
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1651PROGNOSIS ON THE BASIS OF FFR MEASURED
IMMEDIATELY AFTER PCI. Figure 4A displays
the histogram of immediate post-PCI measurements
of FFR, whereas Figure 4B depicts the correspond-
ing Kaplan-Meier survival curves by tertiles. FFR
measured after PCI showed an inverse relation-
ship with subsequent events in both continuous
(Cox hazard ratio: 0.86, 95% conﬁdence interval
[CI]: 0.80 to 0.93; p < 0.001) and tertile (log-
rank p < 0.001) analyses. Adjusting for both pre-
and post-PCI measurements demonstrated that
the ﬁnal FFR value retained prognostic value
(adjusted Cox hazard ratio: 0.90, 95% CI: 0.82
to 0.99; p ¼ 0.032) unlike baseline FFR (adjusted
Cox hazard ratio: 0.97, 95% CI: 0.92 to 1.02;
p ¼ 0.28).
META-ANALYSIS OF STRATEGY-BASED STUDIES.
Table 3 summarizes the 10 studies totaling more than
15,000 patients that compared an FFR-assisted re-
vascularization strategy to one that only used anat-
omy. Whereas an FFR-assisted strategy led to
treatment roughly half as often as an anatomy-based
strategy, it not only lowered MACE by at least
20% but also provided superior angina relief of at
least 10%.DISCUSSION
We demonstrated that FFR provides a continuous
and independent marker of subsequent MACE as
modulated by treatment (medical therapy vs. revas-
cularization) in a broad range of clinical scenarios
comprising thousands of patients from more than 12
countries and spanning more than 15 years of publi-
cations. Both the study-level analysis in Figure 3A
and patient-level analysis in Figure 3B support the
conceptual hypothesis proposed in the Central
Illustration. Therefore, FFR can be seen not only as a
physiologic “biomarker,” because of its continuous
and independent relationship to outcomes, but also
as a target for treatment because revascularization
alters the outcome curve.
As a clear corollary from the conceptual curve in
the Central Illustration, revascularization offers a
greater absolute beneﬁt for more severe FFR values.
Close to either side of the FFR threshold, the net
beneﬁt or risk from PCI or CABG therapy remains
small. By analogy to the idea of “tailored treatment”
for disease spectrums such as hypercholesterolemia
(7), FFR provides the clinician with an objective tool
to personalize risk/beneﬁt tradeoffs continuously
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concept that ischemia exists not as a dichotomous
state, but rather as a graded continuum.
The FFR distributions in Figure 2 highlight the
major limitation of our analysis, namely that the FFR
value strongly inﬂuenced the treatment decision—
what has been termed “confounding by indication” in
the epidemiology literature. As a result, we possess a
limited understanding of the natural history of low
FFR lesions. For example, unrevascularized lesions
with an FFR <0.75 made up less than 2% of all medi-
cally treated lesions in Figure 2B. Although we used
various statistical techniques to compensate, all FFR
threshold values in Table 2 should be considered
only as hypothesis generating. The ongoing FAME-2
(Fractional Flow Reserve versus Angiography for
Multivessel Evaluation-2) trial (5) randomized 441
patients to initial medical therapy with 625 lesions
having FFR #0.80 (mean FFR 0.68  0.15). Compared
to the 443 medically treated lesions with FFR#0.80 in
our meta-analysis (mean FFR 0.77), the 2-year primary
endpoint results from the FAME-2 trial will provide a
larger, more severe, and randomized exploration of
outcomes for medically treated lesions with low FFR.
Rather than changing the FFR thresholds of 0.75
or 0.80 validated in randomized outcomes trials
(3–5), our analysis should be interpreted generally as
supporting a larger treatment beneﬁt from revascu-
larization at lower FFR values. As made explicit by
Figure 3 and Table 2, a range of plausible FFR thresh-
olds exists in our data depending on the clinical
endpoint, statistical model, patient versus population
analysis, and subgroup. However, our results can be
used to enrich revascularization beneﬁt when using
FFR either for clinical care or in future research trials.
In the lesion-level FFR histogram in Figure 2B, a
majority of FFR measurements (3,595 of 6,879; 52%)
exceeded 0.80. This prevalence of high FFR reﬂects a
combination of the patient population referred for
invasive angiography and also lesion selection by
operators for FFR measurement. As with other
“normal rates” for medical tests or surgical pro-
cedures (e.g., myocardial perfusion imaging, invasive
angiography, or appendectomy), no speciﬁc limits
can or should be imposed. In any particular case,
clinical judgment and integration of all available data
must guide patient care. Rather, Figure 2B suggests
that prevalence of high FFR could provide a system-
level metric when studying patterns of CAD care, in-
dependent of classic angiographic metrics that
correlate poorly with physiology.
Immediate post-PCI measurements of FFR carry
prognostic value with an inverse relationship to
subsequent clinical events. Indeed, pre-PCI FFRvalues no longer showed a statistically signiﬁcant
association with events after accounting for post-PCI
FFR measurements in that subgroup. Although
revascularization can “reset” the numerical FFR
value, clearly the event rates in Figure 4 after PCI
remain higher than matched, unrevascularized levels
in Figure 3. Therefore, the prognostic value of the
same FFR number differs between no-PCI and im-
mediate post-PCI scenarios. Additionally, these re-
sults suggest a mechanism for the inverse prognostic
gradient for post-PCI FFR, namely residual diffuse
disease (assuming optimal stent implantation). Other
potential mechanisms appear unlikely, as PCI largely
removed focal disease. Microvascular dysfunction,
which carries an adverse prognosis (8), would lower
hyperemic ﬂow levels and therefore raise the FFR
value, creating a direct relationship between post-PCI
FFR and outcomes, opposite to the observed pattern.
The technique of meta-analysis historically devel-
oped to summarize treatment effects. By contrast,
FFR provides a diagnostic test. Although meta-
analyses have been extended to diagnostic pro-
cedures, they require a reference metric to judge
performance. Our technique used outcomes as the
patient-relevant gold standard to link the diagnostic
test of FFR to treatment choices of medical therapy or
revascularization for CAD. Alternatively, several prior
studies compared an FFR-assisted to an anatomy-
based decision strategy that, however, does not
directly address the “threshold continuum” of our
analysis. As summarized in Table 3, their results
indicate superior clinical outcomes and freedom from
angina with an FFR-guided strategy while reducing
the need for PCI or CABG. Together, these results
provide different yet additive clinical insights linking
FFR-based physiology to outcomes.
COMPARISON TO EXISTING PUBLISHED DATA.
Because our analysis draws from the existing FFR
literature, its ﬁndings parallel but extend and inte-
grate prior publications with new insights on the
continuous spectrum of FFR and its outcomes. The
conceptual curve in the Central Illustration for FFR
appears similar to work using nuclear perfusion im-
aging (9) in that “ischemia” by either technique re-
lates continuously to outcomes as modulated by
treatment (medical therapy vs. revascularization).
Preliminary results from the FAME-2 study (10)
mirror the continuous relationship between FFR for
untreated lesions and subsequent outcomes as seen
in our Figure 3. Additionally, the signiﬁcant treatment
interaction reported in the FAME-2 trial, showing
larger beneﬁt for PCI when FFR <0.65 and smaller
beneﬁt when FFR $0.65 (5), supports the similar
threshold values found in our Table 2. Both of these
PERSPECTIVES
COMPETENCY IN PATIENT CARE: A strategy based on FFR
leads to revascularization roughly half as often as one based only
on coronary anatomy and lowers major adverse cardiac events by
at least 20% while providing superior angina relief.
COMPETENCY IN INTERPERSONAL & COMMUNICATION
SKILLS: In discussions with patients about the balance between
risk and beneﬁt from coronary revascularization, physicians can
explain FFR as an objective, continuous variable that informs
personalized treatment decisions.
TRANSLATIONAL OUTLOOK: The results of future clinical
trials will help reﬁne the role of FFR to guide revascularization
decisions in various patient populations, including measurements
made immediately after PCI.
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at completion of its primary 2-year endpoint analysis.
Therefore, patient-level FAME-2 trial data was
excluded from this analysis (5).
STUDY LIMITATIONS. Similar to any meta-analysis,
our study shares the limitations of its primary sour-
ces. Almost all of the study- and patient-level data
comes from nonrandomized, observational designs.
Baseline characteristics reported in Table 1 were
neither standardized nor collected uniformly among
publications. Clinical endpoints (death, MI, and
revascularization) largely did not undergo blinded
adjudication or have common deﬁnitions. PCI tech-
niques spanned the entire spectrum from balloon-only
angioplasty to the latest drug-eluting stents. Admin-
istered treatment closely followed the FFR value and
was rarely randomized (“confounding by indication”).
As demonstrated by intravascular ultrasound, a
signiﬁcant number of subsequent events do not arise
from the stenosis of interest. Roughly half of all events
in a prospective study following a baseline acute cor-
onary syndrome arose from nonculprit sites (11.6%
from nonculprits alone compared to 20.4% cumulative
event rate) after a median of 3.4 years (11). Therefore,
an important number of events in our meta-analysis
may be unrelated to the lesion interrogated with
FFR. Performance or deferral of focal revasculariza-
tion on the lesion examined using FFR would not be
expected to alter the natural history of these remote
plaques. Similarly, noncardiac deaths and some car-
diac deaths may not be caused by the lesion measured
with FFR. Such nuanced classiﬁcation of subsequent
clinical events as related or unrelated to the FFR lesion
was largely absent from the primary studies.
Our analysis did not address in detail the amount of
myocardium at risk distal to a lesion undergoing FFR
measurement. We hypothesize that the same numeric
FFR value has greater prognostic importance when
the distal mass is large. Therefore, although the higher
FFR threshold seen for left main stenosis in Table 2
makes intuitive sense, we could not explore the
issue further due to lack of an angiographic risk score.
Finally, the conceptual curve in the Central
Illustration might be too simplistic. At low FFR
values, a larger proportion of net myocardial ﬂow
often comes from the collateral circulation (12). A
broad literature assessment has demonstrated a bet-
ter prognosis in patients with more mature collaterals
(13). Therefore, it may be possible that a low FFR in-
ﬂection point exists in the Central Illustration for un-
treated lesions, below which event rates ﬂatten or
even decrease. The natural history of medically
treated lesions with very low FFR values will become
available from the FAME-2 trial.CONCLUSIONS
FFR demonstrates a continuous and independent
relationship between its numeric value and sub-
sequent outcomes, modulated by medical therapy
versus revascularization. Lesions with lower FFR
values receive larger absolute beneﬁts from PCI or
CABG. Outcome-derived FFR thresholds on the basis
of a composite MACE of death, MI, and revasculari-
zation generally fall around the range of 0.75 to 0.80,
although limited due to confounding by indication.
Measurement of FFR immediately after PCI also
shows an inverse gradient of risk, likely from residual
diffuse disease. An FFR-guided revascularization
strategy signiﬁcantly reduces MACE and increases
freedom from angina with less PCI or CABG than an
anatomy-based strategy.
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